BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG, Healey JS, Yusuf S. Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range. Circulation 2008;118:2029-37. [DOI: 10.1161/circulationaha.107.750000] [Cited by in Crossref: 610] [Cited by in F6Publishing: 198] [Article Influence: 43.6] [Reference Citation Analysis]
Number Citing Articles
1 An J, Niu F, Lang DT, Jazdzewski KP, Le PT, Rashid N, Meissner B, Mendes R, Dills DG, Aranda G, Bruno A. Stroke and Bleeding Risk Associated With Antithrombotic Therapy for Patients With Nonvalvular Atrial Fibrillation in Clinical Practice. J Am Heart Assoc 2015;4:e001921. [PMID: 26187996 DOI: 10.1161/JAHA.115.001921] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
2 Gomes Freitas C, Walsh M, Coutinho EL, Vincenzo de Paola AA, Atallah ÁN. Examining therapeutic equivalence between branded and generic warfarin in Brazil: The WARFA crossover randomized controlled trial. PLoS One 2021;16:e0248567. [PMID: 33793580 DOI: 10.1371/journal.pone.0248567] [Reference Citation Analysis]
3 Burnhope E, Boos CJ. Novel anticoagulants for stroke prevention in atrial fibrillation among diabetics. Diabetes & Vascular Disease 2013;13:51-5. [DOI: 10.1177/1474651413476897] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
4 Lin Y, Xiong H, Su J, Lin J, Zhou Q, Lin M, Zhao W, Peng F. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with hypertrophic cardiomyopathy with non-valvular atrial fibrillation. Heart Vessels 2022. [PMID: 35041061 DOI: 10.1007/s00380-022-02021-2] [Reference Citation Analysis]
5 Jang SW, Rho TH, Kim DB, Cho EJ, Kwon BJ, Park HJ, Shin WS, Kim JH, Lee JM, Moon KW, Oh YS, Yoo KD, Youn HJ, Lee MY, Chung WS, Seung KB, Kim JH. Optimal antithrombotic strategy in patients with atrial fibrillation after coronary stent implantation. Korean Circ J 2011;41:578-82. [PMID: 22125556 DOI: 10.4070/kcj.2011.41.10.578] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
6 Ohara M, Takahashi H, Lee MT, Wen MS, Lee TH, Chuang HP, Luo CH, Arima A, Onozuka A, Nagai R, Shiomi M, Mihara K, Morita T, Chen YT. Determinants of the over-anticoagulation response during warfarin initiation therapy in Asian patients based on population pharmacokinetic-pharmacodynamic analyses. PLoS One 2014;9:e105891. [PMID: 25148255 DOI: 10.1371/journal.pone.0105891] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
7 Poli D, Testa S, Antonucci E, Grifoni E, Paoletti O, Lip GYH. Bleeding and stroke risk in a real-world prospective primary prevention cohort of patients with atrial fibrillation. Chest 2011;140:918-24. [PMID: 21511826 DOI: 10.1378/chest.10-3024] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
8 Lee KN, Choi JI, Boo KY, Kim DY, Kim YG, Oh SK, Baek YS, Lee DI, Roh SY, Shim J, Kim JS, Kim YH. Effectiveness and Safety of Off-label Dosing of Non-vitamin K Antagonist Anticoagulant for Atrial Fibrillation in Asian Patients. Sci Rep 2020;10:1801. [PMID: 32019993 DOI: 10.1038/s41598-020-58665-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
9 Pink J, Lane S, Pirmohamed M, Hughes DA. Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses. BMJ 2011;343:d6333. [PMID: 22042753 DOI: 10.1136/bmj.d6333] [Cited by in Crossref: 106] [Cited by in F6Publishing: 91] [Article Influence: 9.6] [Reference Citation Analysis]
10 Rohla M, Weiss TW, Pecen L, Patti G, Siller-Matula JM, Schnabel RB, Schilling R, Kotecha D, Lucerna M, Huber K, De Caterina R, Kirchhof P. Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF). BMJ Open 2019;9:e022478. [PMID: 30928922 DOI: 10.1136/bmjopen-2018-022478] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 7.7] [Reference Citation Analysis]
11 Oldgren J, Healey JS, Ezekowitz M, Commerford P, Avezum A, Pais P, Zhu J, Jansky P, Sigamani A, Morillo CA, Liu L, Damasceno A, Grinvalds A, Nakamya J, Reilly PA, Keltai K, Van Gelder IC, Yusufali AH, Watanabe E, Wallentin L, Connolly SJ, Yusuf S. Variations in Cause and Management of Atrial Fibrillation in a Prospective Registry of 15 400 Emergency Department Patients in 46 Countries: The RE-LY Atrial Fibrillation Registry. Circulation 2014;129:1568-76. [DOI: 10.1161/circulationaha.113.005451] [Cited by in Crossref: 217] [Cited by in F6Publishing: 89] [Article Influence: 27.1] [Reference Citation Analysis]
12 Swaans MJ, Post MC, Rensing BJ, Boersma LV. Percutaneous left atrial appendage closure for stroke prevention in atrial fibrillation. Neth Heart J 2012;20:161-6. [PMID: 22231152 DOI: 10.1007/s12471-011-0236-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
13 Shendre A, Parmar GM, Dillon C, Beasley TM, Limdi NA. Influence of Age on Warfarin Dose, Anticoagulation Control, and Risk of Hemorrhage. Pharmacotherapy 2018;38:588-96. [PMID: 29393514 DOI: 10.1002/phar.2089] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
14 Clarkesmith DE, Pattison HM, Lip GY, Lane DA. Educational intervention improves anticoagulation control in atrial fibrillation patients: the TREAT randomised trial. PLoS One 2013;8:e74037. [PMID: 24040156 DOI: 10.1371/journal.pone.0074037] [Cited by in Crossref: 121] [Cited by in F6Publishing: 116] [Article Influence: 13.4] [Reference Citation Analysis]
15 Fauchier L, Taillandier S. Geographic variations in the quality of oral anticoagulation with vitamin k antagonists in the era of new anticoagulants. J Am Heart Assoc 2013;2:e000088. [PMID: 23525421 DOI: 10.1161/JAHA.113.000088] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
16 Harrington AR, Armstrong EP, Nolan PE Jr, Malone DC. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation. Stroke 2013;44:1676-81. [PMID: 23549134 DOI: 10.1161/STROKEAHA.111.000402] [Cited by in Crossref: 177] [Cited by in F6Publishing: 62] [Article Influence: 19.7] [Reference Citation Analysis]
17 Singer DE, Hellkamp AS, Yuan Z, Lokhnygina Y, Patel MR, Piccini JP, Hankey GJ, Breithardt G, Halperin JL, Becker RC, Hacke W, Nessel CC, Mahaffey KW, Fox KA, Califf RM; ROCKET AF Investigators. Alternative calculations of individual patient time in therapeutic range while taking warfarin: results from the ROCKET AF trial. J Am Heart Assoc 2015;4:e001349. [PMID: 25736441 DOI: 10.1161/JAHA.114.001349] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
18 Furie KL, Goldstein LB, Albers GW, Khatri P, Neyens R, Turakhia MP, Turan TN, Wood KA. Oral Antithrombotic Agents for the Prevention of Stroke in Nonvalvular Atrial Fibrillation: A Science Advisory for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2012;43:3442-53. [DOI: 10.1161/str.0b013e318266722a] [Cited by in Crossref: 181] [Cited by in F6Publishing: 65] [Article Influence: 18.1] [Reference Citation Analysis]
19 Dogliotti A, Paolasso E, Giugliano RP. Novel oral anticoagulants in atrial fibrillation: a meta-analysis of large, randomized, controlled trials vs warfarin. Clin Cardiol 2013;36:61-7. [PMID: 23338902 DOI: 10.1002/clc.22081] [Cited by in Crossref: 57] [Cited by in F6Publishing: 47] [Article Influence: 6.3] [Reference Citation Analysis]
20 Hijazi Z, Lindbäck J, Alexander JH, Hanna M, Held C, Hylek EM, Lopes RD, Oldgren J, Siegbahn A, Stewart RA, White HD, Granger CB, Wallentin L; ARISTOTLE and STABILITY Investigators. The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. Eur Heart J 2016;37:1582-90. [PMID: 26920728 DOI: 10.1093/eurheartj/ehw054] [Cited by in Crossref: 218] [Cited by in F6Publishing: 182] [Article Influence: 36.3] [Reference Citation Analysis]
21 Sandén P, Renlund H, Svensson PJ, Själander A. Bleeding complications in venous thrombosis patients on well-managed warfarin. J Thromb Thrombolysis 2016;41:351-8. [PMID: 26660340 DOI: 10.1007/s11239-015-1305-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
22 Liu YO, Wang ZN, Chen CY, Zhuang XH, Ruan CG, Zhou Y, Cui YM. Antiplatelet Effect of a Pulaimab [Anti-GPIIb/IIIa F(ab)2 Injection] Evaluated by a Population Pharmacokinetic-pharmacodynamic Model. Curr Drug Metab 2019;20:1060-72. [PMID: 31755383 DOI: 10.2174/1389200220666191122120238] [Reference Citation Analysis]
23 Barra S, Fynn S. Untreated atrial fibrillation in the United Kingdom: Understanding the barriers and treatment options. J Saudi Heart Assoc 2015;27:31-43. [PMID: 25544820 DOI: 10.1016/j.jsha.2014.08.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
24 Chebrolu P, Patil S, Laux TS, Al-Hammadi N, Jain Y, Gage B. Quality of anticoagulation with warfarin in rural Chhattisgarh, India. Indian J Med Res 2020;152:303-7. [PMID: 33107491 DOI: 10.4103/ijmr.IJMR_1201_18] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Urbonas G, Valius L, Šakalytė G, Petniūnas K, Petniūnienė I. The Quality of Anticoagulation Therapy among Warfarin-Treated Patients with Atrial Fibrillation in a Primary Health Care Setting.Medicina (Kaunas). 2019;55. [PMID: 30650565 DOI: 10.3390/medicina55010015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
26 Pelargonio G, Perna F. Periprocedural dabigatran in atrial fibrillation ablation: a new kid on the block. J Cardiovasc Electrophysiol 2013;24:866-8. [PMID: 23647979 DOI: 10.1111/jce.12168] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
27 Blum D, Beaubien-Souligny W, Battistella M, Tseng E, Harel Z, Nijjar J, Nazvitch E, Silver SA, Wald R. Quality Improvement Program Improves Time in Therapeutic Range for Hemodialysis Recipients Taking Warfarin. Kidney Int Rep 2020;5:159-64. [PMID: 32043029 DOI: 10.1016/j.ekir.2019.10.011] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
28 Stambler BS, Ngunga LM. Atrial fibrillation in Sub-Saharan Africa: epidemiology, unmet needs, and treatment options. Int J Gen Med 2015;8:231-42. [PMID: 26261423 DOI: 10.2147/IJGM.S84537] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 2.9] [Reference Citation Analysis]
29 Yan CH, Naveed M, Alobaidi A, Kopfman M, Nutescu EA, Sharp LK, Cannegieter DS. Association between transportation barriers and anticoagulation control among an inner-city, low-income population: A prospective observational cohort study. Res Pract Thromb Haemost 2021;5:e12605. [PMID: 34755020 DOI: 10.1002/rth2.12605] [Reference Citation Analysis]
30 Gómez-Outes A, Terleira-Fernández AI, Calvo-Rojas G, Suárez-Gea ML, Vargas-Castrillón E. Direct oral anticoagulants for stroke prevention in patients with atrial fibrillation: meta-analysis by geographic region with a focus on European patients. Br J Clin Pharmacol 2016;82:633-44. [PMID: 27161800 DOI: 10.1111/bcp.13005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
31 Proietti M, Lane DA, Lip GYH. Chronic Kidney Disease, Time in Therapeutic Range and Adverse Clinical Outcomes in Anticoagulated Patients with Non-valvular Atrial Fibrillation: Observations from the SPORTIF Trials. EBioMedicine 2016;8:309-16. [PMID: 27428440 DOI: 10.1016/j.ebiom.2016.04.013] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
32 Limdi NA, Brown TM, Shendre A, Liu N, Hill CE, Beasley TM. Quality of anticoagulation control and hemorrhage risk among African American and European American warfarin users. Pharmacogenet Genomics 2017;27:347-55. [PMID: 28806200 DOI: 10.1097/FPC.0000000000000298] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 4.3] [Reference Citation Analysis]
33 Ng DL, Malik NMBA, Chai CS, Goh GM, Tan SB, Bee PC, Gan GG, Said AB. Time in therapeutic range, quality of life and treatment satisfaction of patients on long-term warfarin for non-valvular atrial fibrillation: a cross-sectional study. Health Qual Life Outcomes 2020;18:347. [PMID: 33081816 DOI: 10.1186/s12955-020-01600-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
34 van Diepen S, Hellkamp AS, Patel MR, Becker RC, Breithardt G, Hacke W, Halperin JL, Hankey GJ, Nessel CC, Singer DE, Berkowitz SD, Califf RM, Fox KA, Mahaffey KW. Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF. Circ Heart Fail 2013;6:740-7. [PMID: 23723250 DOI: 10.1161/CIRCHEARTFAILURE.113.000212] [Cited by in Crossref: 74] [Cited by in F6Publishing: 31] [Article Influence: 8.2] [Reference Citation Analysis]
35 Van Spall HG, Wallentin L, Yusuf S, Eikelboom JW, Nieuwlaat R, Yang S, Kabali C, Reilly PA, Ezekowitz MD, Connolly SJ. Variation in Warfarin Dose Adjustment Practice Is Responsible for Differences in the Quality of Anticoagulation Control Between Centers and Countries: An Analysis of Patients Receiving Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial. Circulation 2012;126:2309-16. [DOI: 10.1161/circulationaha.112.101808] [Cited by in Crossref: 114] [Cited by in F6Publishing: 35] [Article Influence: 11.4] [Reference Citation Analysis]
36 García-Sempere A, Hurtado I, Bejarano-Quisoboni D, Rodríguez-Bernal C, Santa-Ana Y, Peiró S, Sanfélix-Gimeno G. Quality of INR control and switching to non-Vitamin K oral anticoagulants between women and men with atrial fibrillation treated with Vitamin K Antagonists in Spain. A population-based, real-world study. PLoS One 2019;14:e0211681. [PMID: 30753227 DOI: 10.1371/journal.pone.0211681] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
37 Ahmad Y, Lip GY. Stroke Prevention in Atrial Fibrillation: Where are We Now? Clin Med Insights Cardiol 2012;6:65-78. [PMID: 22408371 DOI: 10.4137/CMC.S8976] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
38 Capodanno D, Angiolillo DJ. Management of antiplatelet and anticoagulant therapy in patients with atrial fibrillation in the setting of acute coronary syndromes or percutaneous coronary interventions. Circ Cardiovasc Interv 2014;7:113-24. [PMID: 24550531 DOI: 10.1161/CIRCINTERVENTIONS.113.001150] [Cited by in Crossref: 50] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
39 Silva PGMBE, Sznejder H, Vasconcellos R, Charles GM, Mendonca-Filho HTF, Mardekian J, Nascimento R, Dukacz S, Fusco MD. Anticoagulation Therapy in Patients with Non-valvular Atrial Fibrillation in a Private Setting in Brazil: A Real-World Study. Arq Bras Cardiol 2020;114:457-66. [PMID: 32049154 DOI: 10.36660/abc.20180076] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
40 Medi C, Hankey GJ, Freedman SB. Stroke Risk and Antithrombotic Strategies in Atrial Fibrillation. Stroke 2010;41:2705-13. [DOI: 10.1161/strokeaha.110.589218] [Cited by in Crossref: 49] [Cited by in F6Publishing: 16] [Article Influence: 4.1] [Reference Citation Analysis]
41 Harel Z, Sholzberg M, Shah PS, Pavenski K, Harel S, Wald R, Bell CM, Perl J. Comparisons between novel oral anticoagulants and vitamin K antagonists in patients with CKD. J Am Soc Nephrol 2014;25:431-42. [PMID: 24385595 DOI: 10.1681/ASN.2013040361] [Cited by in Crossref: 76] [Cited by in F6Publishing: 19] [Article Influence: 9.5] [Reference Citation Analysis]
42 Pundi KN, Perino AC, Fan J, Schmitt S, Kothari M, Szummer K, Askari M, Heidenreich PA, Turakhia MP. Direct Oral Anticoagulant Adherence of Patients With Atrial Fibrillation Transitioned from Warfarin. J Am Heart Assoc 2021;10:e020904. [PMID: 34779243 DOI: 10.1161/JAHA.121.020904] [Reference Citation Analysis]
43 Connolly SJ, Eikelboom J, Dorian P, Hohnloser SH, Gretler DD, Sinha U, Ezekowitz MD. Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa). Eur Heart J 2013;34:1498-505. [PMID: 23487517 DOI: 10.1093/eurheartj/eht039] [Cited by in Crossref: 78] [Cited by in F6Publishing: 69] [Article Influence: 8.7] [Reference Citation Analysis]
44 Choumane NS, Malaeb DN, Malaeb B, Hallit S. A multicenter, prospective study evaluating the impact of the clinical pharmacist-physician counselling on warfarin therapy management in Lebanon. BMC Health Serv Res 2018;18:80. [PMID: 29391010 DOI: 10.1186/s12913-018-2874-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
45 Harburger JM, Aronow WS. Newer anticoagulants for non-valvular atrial fibrillation. Pharmaceuticals (Basel) 2012;5:469-80. [PMID: 24281558 DOI: 10.3390/ph5050469] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
46 Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e44S-e88S. [PMID: 22315269 DOI: 10.1378/chest.11-2292] [Cited by in Crossref: 941] [Cited by in F6Publishing: 717] [Article Influence: 94.1] [Reference Citation Analysis]
47 Endres M, Grond M, Hacke W, Ebinger M, Schellinger PD, Dichgans M. [Difficult decisions in stroke therapy]. Nervenarzt 2011;82:957-72. [PMID: 21789692 DOI: 10.1007/s00115-011-3259-x] [Reference Citation Analysis]
48 Albabtain MA, Alharthi MM, Dagriri K, Arafat AA, Ayrout E, Alhebaishi Y, AlFagih A. Assessment of the quality of anticoagulation management with warfarin in a tertiary care center. Saudi Med J 2020;41:1245-51. [PMID: 33130846 DOI: 10.15537/smj.2020.11.25456] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
49 Friberg L, Oldgren J. Efficacy and safety of non-vitamin K antagonist oral anticoagulants compared with warfarin in patients with atrial fibrillation. Open Heart 2017;4:e000682. [PMID: 29018536 DOI: 10.1136/openhrt-2017-000682] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
50 Cano LM, Cardona P, Quesada H, Lara B, Rubio F. Ischaemic stroke in patients treated with oral anticoagulants. Neurologia 2016;31:395-400. [PMID: 25529172 DOI: 10.1016/j.nrl.2014.09.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
51 Mani H, Lindhoff-Last E. New oral anticoagulants in patients with nonvalvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectiveness. Drug Des Devel Ther 2014;8:789-98. [PMID: 24970997 DOI: 10.2147/DDDT.S45644] [Cited by in Crossref: 73] [Cited by in F6Publishing: 23] [Article Influence: 9.1] [Reference Citation Analysis]
52 Margaglione M, Antonucci E, D'Andrea G, Migliaccio L, Ageno W, Bucherini E, Cosmi B, Falanga A, Martini G, Mastroiacovo D, Paparo C, Poli D, Testa S, Palareti G. Anticoagulation in Italian patients with venous thromboembolism and thrombophilic alterations: findings from START2 register study. Blood Transfus 2020;18:486-95. [PMID: 32955425 DOI: 10.2450/2020.0091-20] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
53 Mckenzie JA, Wilson-Clarke C, Prout J, Campbell J, Douglas RD, Gossell-Williams M. Improving warfarin therapy through implementation of a hospital-based pharmacist managed clinic in Jamaica. Pharm Pract (Granada) 2018;16:1214. [PMID: 30637024 DOI: 10.18549/PharmPract.2018.04.1214] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
54 Mark L, Dani G, Vendrey R, Paragh G, Katona A. Oral anticoagulant therapy and bleeding events with vitamin K antagonists in patients with atrial fibrillation in a Hungarian county hospital. Med Sci Monit 2015;21:518-25. [PMID: 25686556 DOI: 10.12659/MSM.892360] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
55 Singer DE, Hellkamp AS, Piccini JP, Mahaffey KW, Lokhnygina Y, Pan G, Halperin JL, Becker RC, Breithardt G, Hankey GJ, Hacke W, Nessel CC, Patel MR, Califf RM, Fox KA; ROCKET AF Investigators. Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial. J Am Heart Assoc 2013;2:e000067. [PMID: 23525418 DOI: 10.1161/JAHA.112.000067] [Cited by in Crossref: 105] [Cited by in F6Publishing: 59] [Article Influence: 11.7] [Reference Citation Analysis]
56 Carcas AJ, Borobia AM, Velasco M, Abad-Santos F, Díaz MQ, Fernández-Capitán C, Ruiz-Giménez N, Madridano O, Sillero PL; PGX-ACE Spanish Investigators Group. Efficiency and effectiveness of the use of an acenocoumarol pharmacogenetic dosing algorithm versus usual care in patients with venous thromboembolic disease initiating oral anticoagulation: study protocol for a randomized controlled trial. Trials 2012;13:239. [PMID: 23237631 DOI: 10.1186/1745-6215-13-239] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
57 Singer DE, Chang Y, Fang MC, Borowsky LH, Pomernacki NK, Udaltsova N, Go AS. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med. 2009;151:297-305. [PMID: 19721017 DOI: 10.7326/0003-4819-151-5-200909010-00003] [Cited by in Crossref: 460] [Cited by in F6Publishing: 376] [Article Influence: 35.4] [Reference Citation Analysis]
58 Ellis DJ, Usman MH, Milner PG, Canafax DM, Ezekowitz MD. The First Evaluation of a Novel Vitamin K Antagonist, Tecarfarin (ATI-5923), in Patients With Atrial Fibrillation. Circulation 2009;120:1029-35. [DOI: 10.1161/circulationaha.109.856120] [Cited by in Crossref: 57] [Cited by in F6Publishing: 7] [Article Influence: 4.4] [Reference Citation Analysis]
59 Bernaitis N, Ching CK, Chen L, Hon JS, Teo SC, Badrick T, Davey AK, Anoopkumar-Dukie S. A High HASBLED Score Identifies Poor Warfarin Control in Patients Treated for Non-Valvular Atrial Fibrillation in Australia and Singapore. Basic Clin Pharmacol Toxicol 2017;121:499-504. [PMID: 28639436 DOI: 10.1111/bcpt.12836] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
60 Ng DL, Gan GG, Chai CS, Chee KH, Tan KL, Tan SB, Bee PC. Comparing quality of life and treatment satisfaction between patients on warfarin and direct oral anticoagulants: a cross-sectional study. Patient Prefer Adherence 2019;13:1363-73. [PMID: 31616136 DOI: 10.2147/PPA.S204246] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 3.7] [Reference Citation Analysis]
61 Sommerauer C, Schlender L, Krause M, Weißbach S, Rieckert A, Martinez YV, Reeves D, Renom-Guiteras A, Kunnamo I, Sönnichsen A. Effectiveness and safety of vitamin K antagonists and new anticoagulants in the prevention of thromboembolism in atrial fibrillation in older adults - a systematic review of reviews and the development of recommendations to reduce inappropriate prescribing. BMC Geriatr 2017;17:223. [PMID: 29047348 DOI: 10.1186/s12877-017-0573-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
62 Aksan G, Soylu K, Demircan S, Aksoy O, Yanık A, Gedikli Ö, Yüksel S, Şahin M, Yılmaz Ö. Oral anticoagulant therapy and clinical outcomes in patients with atrial fibrillation: a pilot study from a single center registry. Blood Coagul Fibrinolysis 2014;25:688-94. [PMID: 24721807 DOI: 10.1097/MBC.0000000000000127] [Reference Citation Analysis]
63 Mwita JC, Francis JM, Oyekunle AA, Gaenamong M, Goepamang M, Magafu MGMD. Quality of Anticoagulation With Warfarin at a Tertiary Hospital in Botswana.Clin Appl Thromb Hemost. 2018;24:596-601. [PMID: 29258394 DOI: 10.1177/1076029617747413] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
64 Lamontagne S, Basein T, Chang B, Mallela L. A hemodialysis cohort study of protocol-based anticoagulation management. BMC Res Notes 2017;10:66. [PMID: 28126020 DOI: 10.1186/s13104-017-2381-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
65 Camm AJ, Bounameaux H. Edoxaban: a new oral direct factor xa inhibitor. Drugs. 2011;71:1503-1526. [PMID: 21861537 DOI: 10.2165/11595540-000000000-00000] [Cited by in Crossref: 80] [Cited by in F6Publishing: 65] [Article Influence: 7.3] [Reference Citation Analysis]
66 Vestergaard AS, Skjøth F, Larsen TB, Ehlers LH. The importance of mean time in therapeutic range for complication rates in warfarin therapy of patients with atrial fibrillation: A systematic review and meta-regression analysis.PLoS One. 2017;12:e0188482. [PMID: 29155884 DOI: 10.1371/journal.pone.0188482] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
67 McAlister FA, Wiebe N, Hemmelgarn BR. Time in therapeutic range and stability over time for warfarin users in clinical practice: a retrospective cohort study using linked routinely collected health data in Alberta, Canada.BMJ Open. 2018;8:e016980. [PMID: 29382672 DOI: 10.1136/bmjopen-2017-016980] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
68 Nelson WW, Wang L, Baser O, Damaraju CV, Schein JR. Out-of-range INR values and outcomes among new warfarin patients with non-valvular atrial fibrillation. Int J Clin Pharm 2015;37:53-9. [PMID: 25428444 DOI: 10.1007/s11096-014-0038-3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
69 Faxon DP, Eikelboom JW, Berger PB, Holmes DR, Bhatt DL, Moliterno DJ, Becker RC, Angiolillo DJ. Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Coronary Stenting: A North American Perspective: Executive Summary. Circ Cardiovasc Interv 2011;4:522-34. [DOI: 10.1161/circinterventions.111.965186] [Cited by in Crossref: 83] [Cited by in F6Publishing: 29] [Article Influence: 7.5] [Reference Citation Analysis]
70 Testa L, Fasano A, De Sanctis V, Latini RA, Latib A, Oreglia J, De Marco F, Agnifili M, Casavecchia M, Talarico GP, Lanotte S, Pizzocri S, Mattioli R, Mantica M, Bedogni F. Selection of Medications to Prevent Stroke Among Individuals With Atrial Fibrillation : Update on Prevention of Stroke in Patients with AF. Curr Treat Options Neurol 2013;15:583-92. [PMID: 23794179 DOI: 10.1007/s11940-013-0248-3] [Reference Citation Analysis]
71 Bang OY, Hong KS, Heo JH, Koo J, Kwon SU, Yu KH, Bae HJ, Lee BC, Yoon BW, Kim JS. New oral anticoagulants may be particularly useful for asian stroke patients. J Stroke 2014;16:73-80. [PMID: 24949312 DOI: 10.5853/jos.2014.16.2.73] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
72 Pivatto Junior F, Scheffel RS, Ries L, Wolkind RR, Marobin R, Barkan SS, Amon LC, Biolo A. SAMe-TT2R2 Score in the Outpatient Anticoagulation Clinic to Predict Time in Therapeutic Range and Adverse Events. Arq Bras Cardiol 2017;108:290-6. [PMID: 28538758 DOI: 10.5935/abc.20170052] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
73 Homma S, Thompson JL, Qian M, Ye S, Di Tullio MR, Lip GY, Mann DL, Sacco RL, Levin B, Pullicino PM, Freudenberger RS, Teerlink JR, Graham S, Mohr JP, Labovitz AJ, Buchsbaum R, Estol CJ, Lok DJ, Ponikowski P, Anker SD; WARCEF Investigators. Quality of anticoagulation control in preventing adverse events in patients with heart failure in sinus rhythm: Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial substudy. Circ Heart Fail 2015;8:504-9. [PMID: 25850425 DOI: 10.1161/CIRCHEARTFAILURE.114.001725] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 2.6] [Reference Citation Analysis]
74 Nieuwlaat R, Connolly SJ, Mackay JA, Weise-Kelly L, Navarro T, Wilczynski NL, Haynes RB; CCDSS Systematic Review Team. Computerized clinical decision support systems for therapeutic drug monitoring and dosing: a decision-maker-researcher partnership systematic review. Implement Sci 2011;6:90. [PMID: 21824384 DOI: 10.1186/1748-5908-6-90] [Cited by in Crossref: 54] [Cited by in F6Publishing: 53] [Article Influence: 4.9] [Reference Citation Analysis]
75 Li A, Behr ER. Advances in the management of atrial fibrillation. Clin Med (Lond) 2012;12:544-52. [PMID: 23342409 DOI: 10.7861/clinmedicine.12-6-544] [Reference Citation Analysis]
76 Putnam A, Gu X, Haymart B, Kline-Rogers E, Almany S, Kozlowski J, Krol GD, Kaatz S, Froehlich JB, Barnes GD. The changing characteristics of atrial fibrillation patients treated with warfarin. J Thromb Thrombolysis 2015;40:488-93. [PMID: 26130229 DOI: 10.1007/s11239-015-1244-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
77 Kirchhof P, Lip GY, Van Gelder IC, Bax J, Hylek E, Kaab S, Schotten U, Wegscheider K, Boriani G, Brandes A. Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options--a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference. Europace. 2012;14:8-27. [PMID: 21791573 DOI: 10.1093/europace/eur241] [Cited by in Crossref: 145] [Cited by in F6Publishing: 122] [Article Influence: 13.2] [Reference Citation Analysis]
78 Krittayaphong R, Winijkul A, Pirapatdit A, Chiewvit P, Komoltri C, Boonyapisit W, Arunsiriwattana S, Bunyapipat T, Apiyasawat S, Rattanasumawong K, Yindeengam A; Cool-AF Investigators. SAMe-TT2R2 score for prediction of suboptimal time in therapeutic range in a Thai population with atrial fibrillation. Singapore Med J 2020;61:641-6. [PMID: 31680175 DOI: 10.11622/smedj.2019143] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
79 Efird LM, Miller DR, Ash AS, Berlowitz DR, Ozonoff A, Zhao S, Reisman JI, Jasuja GK, Rose AJ. Identifying the risks of anticoagulation in patients with substance abuse. J Gen Intern Med 2013;28:1333-9. [PMID: 23620189 DOI: 10.1007/s11606-013-2453-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
80 Gómez-Outes A, Terleira-Fernández AI, Calvo-Rojas G, Suárez-Gea ML, Vargas-Castrillón E. Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups. Thrombosis 2013;2013:640723. [PMID: 24455237 DOI: 10.1155/2013/640723] [Cited by in Crossref: 99] [Cited by in F6Publishing: 85] [Article Influence: 11.0] [Reference Citation Analysis]
81 Dlott JS, George RA, Huang X, Odeh M, Kaufman HW, Ansell J, Hylek EM. National assessment of warfarin anticoagulation therapy for stroke prevention in atrial fibrillation. Circulation 2014;129:1407-14. [PMID: 24493817 DOI: 10.1161/CIRCULATIONAHA.113.002601] [Cited by in Crossref: 105] [Cited by in F6Publishing: 35] [Article Influence: 13.1] [Reference Citation Analysis]
82 Camm AJ, Lip GY, Caterina RD, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, Mcdonagh T, Moulin C, Popescu BA, Reiner Ž, Sechtem U, Anton Sirnes P, Tendera M, Torbicki A, Vahanian A, Windecker S, Vardas P, Al-attar N, Alfieri O, Angelini A, Blömstrom-lundqvist C, Colonna P, De Sutter J, Ernst S, Goette A, Gorenek B, Hatala R, Heidbüchel H, Heldal M, Dalby Kristensen S, Kolh P, Le Heuzey J, Mavrakis H, Mont L, Perrone Filardi P, Ponikowski P, Prendergast B, Rutten FH, Schotten U, Van Gelder IC, Verheugt FW. Actualización detallada de las guías de la ESC para el manejo de la fibrilación auricular de 2012. Revista Española de Cardiología 2013;66:54.e1-54.e24. [DOI: 10.1016/j.recesp.2012.11.001] [Cited by in Crossref: 10] [Article Influence: 1.1] [Reference Citation Analysis]
83 Otsuki H, Yamaguchi J, Kamishima K, Arashi H, Hagiwara N. Real-world antithrombotic therapies and clinical outcomes after second-generation drug-eluting stent implantation in patients with atrial fibrillation: a multi-center cohort study. Heart Vessels 2018;33:986-96. [PMID: 29549436 DOI: 10.1007/s00380-018-1148-y] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
84 Aimo A, Giugliano RP, De Caterina R. Non–Vitamin K Antagonist Oral Anticoagulants for Mechanical Heart Valves: Is the Door Still Open? Circulation 2018;138:1356-65. [DOI: 10.1161/circulationaha.118.035612] [Cited by in Crossref: 19] [Cited by in F6Publishing: 2] [Article Influence: 4.8] [Reference Citation Analysis]
85 Shiyovich A, Shalev V, Chodick G, Tirosh M, Katz A, Klar MM, Shuvy M, Pereg D, Minha S. Shifting from vitamin K antagonists to non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: predictors, patterns and temporal trends. BMC Cardiovasc Disord 2021;21:493. [PMID: 34645389 DOI: 10.1186/s12872-021-02295-w] [Reference Citation Analysis]
86 Naccarelli GV, Caputo G, Abendroth T, Faber S, Sendra-ferrer M, Wolbrette D, Samii S, Hussain S, Gonzalez M. Stroke Prevention in Atrial Fibrillation: Current Strategies and Recommendations. Cardiovascular Innovations and Applications 2016;1:157-64. [DOI: 10.15212/cvia.2016.0005] [Reference Citation Analysis]
87 Blissit KT, Mullenix ML, Brittain KG. Evaluation of Time in Therapeutic Range on Warfarin Therapy Between Face-to-Face and Telephone Follow-Up in a VA Medical Center. J Pharm Technol 2015;31:78-83. [PMID: 34860994 DOI: 10.1177/8755122514552497] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
88 Tran HN, Tafreshi J, Hernandez EA, Pai SM, Torres VI, Pai RG. A multidisciplinary atrial fibrillation clinic. Curr Cardiol Rev 2013;9:55-62. [PMID: 23092274 DOI: 10.2174/157340313805076287] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
89 Boned-Ombuena A, Pérez-Panadés J, López-Maside A, Miralles-Espí M, Guardiola Vilarroig S, Adam Ruiz D, Zurriaga O. [Prevalence of oral anticoagulation and quality of its management in primary healthcare: A study by the Health Sentinel Network of the Region of Valencia (Spain)]. Aten Primaria 2017;49:534-48. [PMID: 28408116 DOI: 10.1016/j.aprim.2016.11.015] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
90 Abell L, Irwin AN. Evaluation of Warfarin Use in Patients With Mental Health Conditions in a Rural Community Health Center System. J Pharm Technol 2021;37:17-22. [PMID: 34752554 DOI: 10.1177/8755122520960226] [Reference Citation Analysis]
91 Gallego P, Vilchez JA, Lane DA. Apixaban Compared With Warfarin for Stroke Prevention in Atrial Fibrillation: Implications of Time in Therapeutic Range. Circulation 2013;127:2163-5. [DOI: 10.1161/circulationaha.113.003132] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
92 Wallentin L, Lopes RD, Hanna M, Thomas L, Hellkamp A, Nepal S, Hylek EM, Al-khatib SM, Alexander JH, Alings M, Amerena J, Ansell J, Aylward P, Bartunek J, Commerford P, De Caterina R, Erol C, Harjola V, Held C, Horowitz JD, Huber K, Husted S, Keltai M, Lanas F, Lisheng L, Mcmurray JJ, Oh B, Rosenqvist M, Ruzyllo W, Steg PG, Vinereanu D, Xavier D, Granger CB. Efficacy and Safety of Apixaban Compared With Warfarin at Different Levels of Predicted International Normalized Ratio Control for Stroke Prevention in Atrial Fibrillation. Circulation 2013;127:2166-76. [DOI: 10.1161/circulationaha.112.142158] [Cited by in Crossref: 151] [Cited by in F6Publishing: 59] [Article Influence: 16.8] [Reference Citation Analysis]
93 Rose AJ, Berlowitz DR, Ash AS, Ozonoff A, Hylek EM, Goldhaber-Fiebert JD. The business case for quality improvement: oral anticoagulation for atrial fibrillation. Circ Cardiovasc Qual Outcomes 2011;4:416-24. [PMID: 21712521 DOI: 10.1161/CIRCOUTCOMES.111.960591] [Cited by in Crossref: 37] [Cited by in F6Publishing: 10] [Article Influence: 3.4] [Reference Citation Analysis]
94 Essien UR, Holmes DN, Jackson LR 2nd, Fonarow GC, Mahaffey KW, Reiffel JA, Steinberg BA, Allen LA, Chan PS, Freeman JV, Blanco RG, Pieper KS, Piccini JP, Peterson ED, Singer DE. Association of Race/Ethnicity With Oral Anticoagulant Use in Patients With Atrial Fibrillation: Findings From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II. JAMA Cardiol 2018;3:1174-82. [PMID: 30484833 DOI: 10.1001/jamacardio.2018.3945] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 15.0] [Reference Citation Analysis]
95 Eckman MH, Greenberg SM, Rosand J. Should we test for CYP2C9 before initiating anticoagulant therapy in patients with atrial fibrillation? J Gen Intern Med 2009;24:543-9. [PMID: 19255811 DOI: 10.1007/s11606-009-0927-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
96 Ho C, Ho M, Chan P, Hai J, Cheung E, Yeung C, Lau K, Chan K, Lau C, Lip GY, Leung GK, Tse H, Siu C. Ischemic Stroke and Intracranial Hemorrhage With Aspirin, Dabigatran, and Warfarin: Impact of Quality of Anticoagulation Control. Stroke 2015;46:23-30. [DOI: 10.1161/strokeaha.114.006476] [Cited by in Crossref: 77] [Cited by in F6Publishing: 25] [Article Influence: 11.0] [Reference Citation Analysis]
97 Marcatto LR, Sacilotto L, Tavares LC, Souza DSP, Olivetti N, Strunz CMC, Darrieux FCC, Scanavacca MI, Krieger JE, Pereira AC, Santos PCJL. Evaluation of the Long-Term Impact on Quality After the End of Pharmacist-Driven Warfarin Therapy Management in Patients With Poor Quality of Anticoagulation Therapy. Front Pharmacol 2020;11:1056. [PMID: 32765269 DOI: 10.3389/fphar.2020.01056] [Reference Citation Analysis]
98 You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, Hylek EM, Schulman S, Go AS, Hughes M, Spencer FA, Manning WJ, Halperin JL, Lip GYH. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e531S-75S. [PMID: 22315271 DOI: 10.1378/chest.11-2304] [Cited by in Crossref: 603] [Cited by in F6Publishing: 521] [Article Influence: 60.3] [Reference Citation Analysis]
99 Mearns ES, Hawthorne J, Song JS, Coleman CI. Measures of vitamin K antagonist control reported in atrial fibrillation and venous thromboembolism studies: a systematic review. BMJ Open 2014;4:e005379. [PMID: 24951111 DOI: 10.1136/bmjopen-2014-005379] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
100 Bikdeli B, Gupta A, Mody P, Lampropulos JF, Dharmarajan K; for the Editor. Most Important Outcomes Research Papers on Anticoagulation for Cardiovascular Disease. Circ: Cardiovascular Quality and Outcomes 2012;5. [DOI: 10.1161/circoutcomes.112.968701] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
101 Ueberham L, Dagres N, Potpara TS, Bollmann A, Hindricks G. Pharmacological and Non-pharmacological Treatments for Stroke Prevention in Patients with Atrial Fibrillation. Adv Ther 2017;34:2274-94. [PMID: 28956288 DOI: 10.1007/s12325-017-0616-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
102 Cao L, Pokorney SD, Hayden K, Welsh-Bohmer K, Newby LK. Cognitive Function: Is There More to Anticoagulation in Atrial Fibrillation Than Stroke? J Am Heart Assoc 2015;4:e001573. [PMID: 26240065 DOI: 10.1161/JAHA.114.001573] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 2.4] [Reference Citation Analysis]
103 Rogge C, Hilbert S, Dagres N, Hindricks G. [Current state of treatment strategies for atrial fibrillation]. Herz 2016;41:253-66; quiz 267-9. [PMID: 27067008 DOI: 10.1007/s00059-016-4413-9] [Reference Citation Analysis]
104 Cho H, Kang J, Kim HS, Park KW. Ethnic Differences in Oral Antithrombotic Therapy. Korean Circ J 2020;50:645-57. [PMID: 32725974 DOI: 10.4070/kcj.2020.0098] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
105 Te ALD, Chao T, Chen S. Optimizing Anticoagulation in Older Patients with Nonvalvular Atrial Fibrillation. Curr Cardiovasc Risk Rep 2019;13. [DOI: 10.1007/s12170-019-0599-8] [Reference Citation Analysis]
106 Dahal K, Sharma SP, Fung E, Lee J, Moore JH, Unterborn JN, Williams SM. Meta-analysis of Randomized Controlled Trials of Genotype-Guided vs Standard Dosing of Warfarin. Chest 2015;148:701-10. [PMID: 25811981 DOI: 10.1378/chest.14-2947] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 2.9] [Reference Citation Analysis]
107 Sage W, Gottiparthy A, Lincoln P, Tsui SSL, Pettit SJ. Improving anticoagulation of patients with an implantable left ventricular assist device. BMJ Open Qual 2018;7:e000250. [PMID: 30306143 DOI: 10.1136/bmjoq-2017-000250] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
108 Pollack CV Jr. Coagulation assessment with the new generation of oral anticoagulants. Emerg Med J 2016;33:423-30. [PMID: 25987596 DOI: 10.1136/emermed-2015-204891] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 5.1] [Reference Citation Analysis]
109 Ezekowitz MD, Wallentin L, Connolly SJ, Parekh A, Chernick MR, Pogue J, Aikens TH, Yang S, Reilly PA, Lip GY, Yusuf S; the RE-LY Steering Committee and Investigators. Dabigatran and Warfarin in Vitamin K Antagonist–Naive and –Experienced Cohorts With Atrial Fibrillation. Circulation 2010;122:2246-53. [DOI: 10.1161/circulationaha.110.973735] [Cited by in Crossref: 122] [Cited by in F6Publishing: 39] [Article Influence: 10.2] [Reference Citation Analysis]
110 Flaker GC, Pogue J, Yusuf S, Pfeffer MA, Goldhaber SZ, Granger CB, Anand IS, Hart R, Connolly SJ. Cognitive Function and Anticoagulation Control in Patients With Atrial Fibrillation. Circ Cardiovasc Qual Outcomes 2010;3:277-83. [DOI: 10.1161/circoutcomes.109.884171] [Cited by in Crossref: 75] [Cited by in F6Publishing: 30] [Article Influence: 6.3] [Reference Citation Analysis]
111 Hong KS, Kim YK, Bae HJ, Nam HS, Kwon SU, Bang OY, Cha JK, Yoon BW, Rha JH, Lee BC, Park JM, Park MS, Lee J, Choi JC, Kim DE, Lee KB, Park TH, Lee JS, Kim SE, Lee J. Quality of Anticoagulation with Warfarin in Korean Patients with Atrial Fibrillation and Prior Stroke: A Multicenter Retrospective Observational Study. J Clin Neurol 2017;13:273-80. [PMID: 28748679 DOI: 10.3988/jcn.2017.13.3.273] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
112 Masresha N, Muche EA, Atnafu A, Abdela O. Evaluation of Warfarin Anticoagulation at University of Gondar Comprehensive Specialized Hospital, North-West Ethiopia. J Blood Med 2021;12:189-95. [PMID: 33790682 DOI: 10.2147/JBM.S282948] [Reference Citation Analysis]
113 Clarkesmith DE, Pattison HM, Khaing PH, Lane DA. Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation. Cochrane Database Syst Rev 2017;4:CD008600. [PMID: 28378924 DOI: 10.1002/14651858.CD008600.pub3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
114 Hess PL, Mirro MJ, Diener HC, Eikelboom JW, Al-Khatib SM, Hylek EM, Bosworth HB, Gersh BJ, Singer DE, Flaker G, Mega JL, Peterson ED, Rumsfeld JS, Steinberg BA, Kakkar AK, Califf RM, Granger CB; Atrial Fibrillation Think-Tank Participants. Addressing barriers to optimal oral anticoagulation use and persistence among patients with atrial fibrillation: Proceedings, Washington, DC, December 3-4, 2012. Am Heart J 2014;168:239-247.e1. [PMID: 25173533 DOI: 10.1016/j.ahj.2014.04.007] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 3.9] [Reference Citation Analysis]
115 Rose AJ, Delate T, Ozonoff A, Witt DM. Comparison of the Abilities of Summary Measures of International Normalized Ratio Control to Predict Clinically Relevant Bleeding. Circ Cardiovasc Qual Outcomes 2015;8:524-31. [PMID: 26330391 DOI: 10.1161/CIRCOUTCOMES.115.001768] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
116 Desmaele S, Dupont AG, Putman K, Cornu P, Steurbaut S. Comparison of two approaches of INR-follow-up and determinants of INR-stability. Acta Clin Belg 2015;70:167-74. [PMID: 26103536 DOI: 10.1179/2295333714Y.0000000117] [Reference Citation Analysis]
117 Dallalzadeh LO, Go AS, Chang Y, Borowsky LH, Fang MC, Singer DE. Stability of High-Quality Warfarin Anticoagulation in a Community-Based Atrial Fibrillation Cohort: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. J Am Heart Assoc 2016;5:e003482. [PMID: 27451456 DOI: 10.1161/JAHA.116.003482] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
118 Snipelisky D, Kusumoto F. Current strategies to minimize the bleeding risk of warfarin. J Blood Med 2013;4:89-99. [PMID: 24019755 DOI: 10.2147/JBM.S41404] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
119 Singh P, Kalita J, Misra UK. Quality of anticoagulation therapy in neurological patients in a tertiary care hospital in north India. Indian J Med Res 2016;143:428-33. [PMID: 27377498 DOI: 10.4103/0971-5916.184301] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
120 Singer DE, Chang Y, Fang MC, Borowsky LH, Pomernacki NK, Udaltsova N, Go AS. Should patient characteristics influence target anticoagulation intensity for stroke prevention in nonvalvular atrial fibrillation?: the ATRIA study. Circ Cardiovasc Qual Outcomes 2009;2:297-304. [PMID: 20031854 DOI: 10.1161/CIRCOUTCOMES.108.830232] [Cited by in Crossref: 72] [Cited by in F6Publishing: 34] [Article Influence: 5.5] [Reference Citation Analysis]
121 Hylek EM. Vitamin K antagonists and time in the therapeutic range: implications, challenges, and strategies for improvement. J Thromb Thrombolysis 2013;35:333-5. [PMID: 23456572 DOI: 10.1007/s11239-013-0900-5] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 4.0] [Reference Citation Analysis]
122 Aloysius MM, Perisetti A, Goyal H, Boregowda U, Jecmenica M, Cheryala M, Bajaj A, Milekic B, Babic M, Bansal P, Enders GH. Direct-acting oral anticoagulants versus warfarin in relation to risk of gastrointestinal bleeding: a systematic review and meta-analysis of randomized controlled trials. Ann Gastroenterol 2021;34:651-9. [PMID: 34475735 DOI: 10.20524/aog.2021.0658] [Reference Citation Analysis]
123 Skeppholm M, Friberg L. Adherence to warfarin treatment among patients with atrial fibrillation. Clin Res Cardiol 2014;103:998-1005. [PMID: 25080281 DOI: 10.1007/s00392-014-0742-y] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 4.3] [Reference Citation Analysis]
124 Sjögren V, Byström B, Renlund H, Svensson PJ, Oldgren J, Norrving B, Själander A. Non-vitamin K oral anticoagulants are non-inferior for stroke prevention but cause fewer major bleedings than well-managed warfarin: A retrospective register study. PLoS One 2017;12:e0181000. [PMID: 28700711 DOI: 10.1371/journal.pone.0181000] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
125 Giorgi MA, Caroli C, Giglio ND, Micone P, Aiello E, Vulcano C, Blanco J, Donato B, Quevedo JM. Estimation of the cost-effectiveness of apixaban versus vitamin K antagonists in the management of atrial fibrillation in Argentina. Health Econ Rev 2015;5:52. [PMID: 26112219 DOI: 10.1186/s13561-015-0052-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
126 de Lima Silva RG, Bertollo CM, Ferreira IG, Brant LC, Martins MAP. Assessment of oral anticoagulation control at two pharmacist-managed clinics in Brazil. Int J Clin Pharm 2017;39:1157-61. [PMID: 28932938 DOI: 10.1007/s11096-017-0511-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
127 Lip GY, Rasmussen LH, Olsson SB, Jensen EC, Persson AL, Eriksson U, Wåhlander KF; Steering Committee. Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists. Eur Heart J 2009;30:2897-907. [PMID: 19690349 DOI: 10.1093/eurheartj/ehp318] [Cited by in Crossref: 66] [Cited by in F6Publishing: 55] [Article Influence: 5.1] [Reference Citation Analysis]
128 Perreault S, Shahabi P, Côté R, Dumas S, Rouleau-Mailloux É, Feroz Zada Y, Provost S, Mongrain I, Dorais M, Huynh T, Kouz S, Diaz A, Blostein M, de Denus S, Turgeon J, Ginsberg J, Lelorier J, Lalonde L, Busque L, Kassis J, Talajic M, Tardif JC, Dubé MP. Rationale, design, and preliminary results of the Quebec Warfarin Cohort Study. Clin Cardiol 2018;41:576-85. [PMID: 29542828 DOI: 10.1002/clc.22948] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
129 Botton MR, Viola PP, Meireles MR, Bruxel EM, Zuchinali P, Bandinelli E, Rohde LE, Leiria TLL, Salamoni JYY, Garbin AP, Hutz MH. Identification of environmental and genetic factors that influence warfarin time in therapeutic range. Genet Mol Biol 2020;43:e20190025. [PMID: 32052826 DOI: 10.1590/1678-4685-GMB-2019-0025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
130 Petersen JK, Haider Butt J, Yafasova A, Torp-Pedersen C, Sørensen R, Kruuse C, Vinding NE, Gundlund A, Køber L, Loldrup Fosbøl E, Østergaard L. Incidence of ischaemic stroke and mortality in patients with acute coronary syndrome and first-time detected atrial fibrillation: a nationwide study. Eur Heart J 2021;42:4553-61. [PMID: 34477838 DOI: 10.1093/eurheartj/ehab575] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
131 Atas H, Sahin AA, Barutçu Atas D, Sunbul M, Kepez A, Agirbasli M. Potential Causes and Implications of Low Target Therapeutic Ratio in Warfarin-Treated Patients for Thrombosis Prophylaxis: A Single-Center Experience. Clin Appl Thromb Hemost 2018;24:536-41. [PMID: 28301912 DOI: 10.1177/1076029617695484] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
132 McAlister FA, Mian R, Oldgren J, Wallentin L, Ezekowitz M, Yusuf S, Connolly SJ, Healey JS; RE-LY Atrial Fibrillation Registry Investigators. Hypertension prevalence but not control varies across the spectrum of risk in patients with atrial fibrillation: A RE-LY atrial fibrillation registry sub-study. PLoS One 2020;15:e0226259. [PMID: 31940361 DOI: 10.1371/journal.pone.0226259] [Reference Citation Analysis]
133 Proietti M, Airaksinen KEJ, Rubboli A, Schlitt A, Kiviniemi T, Karjalainen PP, Lip GYH; AFCAS Study Group. Synergic impact of oral anticoagulation control and renal function in determining major adverse events in atrial fibrillation patients undergoing percutaneous coronary intervention: insights from the AFCAS registry. Clin Res Cardiol 2017;106:420-7. [PMID: 28078448 DOI: 10.1007/s00392-016-1071-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
134 Price EL, Ansell J. Virtual Education for Patient Self-Testing for Warfarin Therapy Is Effective During the COVID-19 Pandemic. The Joint Commission Journal on Quality and Patient Safety 2022. [DOI: 10.1016/j.jcjq.2022.01.001] [Reference Citation Analysis]
135 Shah Z, Masoomi R, Tadros P. Managing Antiplatelet Therapy and Anticoagulants in Patients with Coronary Artery Disease and Atrial Fibrillation. J Atr Fibrillation 2015;8:1318. [PMID: 27957230 DOI: 10.4022/jafib.1318] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
136 Marrast L, Evans M, Ozonoff A, Henault LE, Rose AJ. Using highly variable warfarin dosing to identify patients at risk for adverse events. Thromb J 2011;9:14. [PMID: 21985504 DOI: 10.1186/1477-9560-9-14] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
137 Weimar C, Hohnloser SH, Eikelboom JW, Diener HC. Preventing cardioembolic stroke in atrial fibrillation with dabigatran. Curr Neurol Neurosci Rep 2012;12:17-23. [PMID: 21960064 DOI: 10.1007/s11910-011-0229-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
138 You JH, Tsui KK, Wong RS, Cheng G. Cost-effectiveness of dabigatran versus genotype-guided management of warfarin therapy for stroke prevention in patients with atrial fibrillation. PLoS One 2012;7:e39640. [PMID: 22745801 DOI: 10.1371/journal.pone.0039640] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 4.1] [Reference Citation Analysis]
139 Rose AJ, Miller DR, Ozonoff A, Berlowitz DR, Ash AS, Zhao S, Reisman JI, Hylek EM. Gaps in monitoring during oral anticoagulation: insights into care transitions, monitoring barriers, and medication nonadherence. Chest 2013;143:751-7. [PMID: 23187457 DOI: 10.1378/chest.12-1119] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 3.4] [Reference Citation Analysis]
140 You JH. Novel oral anticoagulants vs warfarin therapy at various levels of anticoagulation control in atrial fibrillation--a cost-effectiveness analysis.J Gen Intern Med. 2014;29:438-446. [PMID: 24132628 DOI: 10.1007/s11606-013-2639-2] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 3.8] [Reference Citation Analysis]
141 Caldeira D, Cruz I, Morgado G, Stuart B, Gomes C, Martins C, João I, Pereira H. Evaluation of time in therapeutic range in anticoagulated patients: a single-center, retrospective, observational study. BMC Res Notes 2014;7:891. [PMID: 25491419 DOI: 10.1186/1756-0500-7-891] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
142 Li X, Tse VC, Lau WC, Cheung BM, Lip GY, Wong IC, Chan EW. Cost-Effectiveness of Apixaban versus Warfarin in Chinese Patients with Non-Valvular Atrial Fibrillation: A Real-Life and Modelling Analyses. PLoS One 2016;11:e0157129. [PMID: 27362421 DOI: 10.1371/journal.pone.0157129] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
143 Rodríguez-Bernal CL, García-Sempere A, Hurtado I, Santa-Ana Y, Peiró S, Sanfélix-Gimeno G. Real-world adherence to oral anticoagulants in atrial fibrillation patients: a study protocol for a systematic review and meta-analysis. BMJ Open 2018;8:e025102. [PMID: 30573490 DOI: 10.1136/bmjopen-2018-025102] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
144 Bertomeu-González V, Anguita M, Moreno-Arribas J, Cequier Á, Muñiz J, Castillo-Castillo J, Sanchis J, Roldán I, Marin F, Bertomeu-Martínez V; FANTASIIA Study Investigators. Quality of Anticoagulation With Vitamin K Antagonists. Clin Cardiol 2015;38:357-64. [PMID: 25962838 DOI: 10.1002/clc.22397] [Cited by in Crossref: 55] [Cited by in F6Publishing: 34] [Article Influence: 7.9] [Reference Citation Analysis]
145 Aidit S, Soh YC, Yap CS, Khan TM, Neoh CF, Shaharuddin S, Kassab YW, Patel RP, Ming LC. Effect of Standardized Warfarin Treatment Protocol on Anticoagulant Effect: Comparison of a Warfarin Medication Therapy Adherence Clinic with Usual Medical Care. Front Pharmacol 2017;8:637. [PMID: 29170637 DOI: 10.3389/fphar.2017.00637] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
146 Tosetto A, Manotti C, Marongiu F; Italian Federation of Anticoagulation Clinics (FCSA) clinical quality study group. Center-Related Determinants of VKA Anticoagulation Quality: A Prospective, Multicenter Evaluation. PLoS One 2015;10:e0144314. [PMID: 26636337 DOI: 10.1371/journal.pone.0144314] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
147 Molteni M, Cimminiello C. Warfarin and atrial fibrillation: from ideal to real the warfarin affaire. Thromb J 2014;12:5. [PMID: 24548437 DOI: 10.1186/1477-9560-12-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
148 Mitrousi K, Lip GYH, Apostolakis S. Age as a Risk Factor for Stroke in Atrial Fibrillation Patients: Implications in Thromboprophylaxis in the Era of Novel Oral Anticoagulants. J Atr Fibrillation 2013;6:783. [PMID: 28496851 DOI: 10.4022/jafib.783] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
149 Angiolillo DJ, Goodman SG, Bhatt DL, Eikelboom JW, Price MJ, Moliterno DJ, Cannon CP, Tanguay J, Granger CB, Mauri L, Holmes DR, Gibson CM, Faxon DP. Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective–2018 Update. Circulation 2018;138:527-36. [DOI: 10.1161/circulationaha.118.034722] [Cited by in Crossref: 148] [Cited by in F6Publishing: 38] [Article Influence: 37.0] [Reference Citation Analysis]
150 Arshad A, Johnson CK, Mittal S, Buch E, Hamam I, Tran T, Shaw RE, Musat D, Preminger M, Sichrovsky T, Herweg B, Shivkumar K, Hummel J, Steinberg JS. Comparative safety of periablation anticoagulation strategies for atrial fibrillation: data from a large multicenter study. Pacing Clin Electrophysiol 2014;37:665-73. [PMID: 24797604 DOI: 10.1111/pace.12401] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
151 Razouki Z, Burgess JF Jr, Ozonoff A, Zhao S, Berlowitz D, Rose AJ. Improving Anticoagulation Measurement Novel Warfarin Composite Measure. Circ Cardiovasc Qual Outcomes 2015;8:600-7. [PMID: 26420820 DOI: 10.1161/CIRCOUTCOMES.115.001789] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
152 Pink J, Pirmohamed M, Hughes DA. Comparative effectiveness of dabigatran, rivaroxaban, apixaban, and warfarin in the management of patients with nonvalvular atrial fibrillation. Clin Pharmacol Ther 2013;94:269-76. [PMID: 23619028 DOI: 10.1038/clpt.2013.83] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
153 Martins MAP, Costa JM, Mambrini JVM, Ribeiro ALP, Benjamin EJ, Brant LCC, Paasche-Orlow MK, Magnani JW. Health literacy and warfarin therapy at two anticoagulation clinics in Brazil. Heart 2017;103:1089-95. [PMID: 28258243 DOI: 10.1136/heartjnl-2016-310699] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
154 Nelson WW, Milentijevic D, Wang L, Baser O, Damaraju C, Schein JR. Patterns of international normalized ratio values among new warfarin patients with nonvalvular atrial fibrillation. Blood Coagulation & Fibrinolysis 2016;27:899-906. [DOI: 10.1097/mbc.0000000000000515] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
155 Ciurus T, Cichocka-Radwan A, Lelonek M. Factors affecting the quality of anticoagulation with warfarin: experience of one cardiac centre. Kardiochir Torakochirurgia Pol 2015;12:334-40. [PMID: 26855650 DOI: 10.5114/kitp.2015.56784] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
156 Víquez-Jaikel A, Victoria Hall-Ramírez, Ramos-Esquivel A. Improvement of time in therapeutic range with warfarin by pharmaceutical intervention. Int J Clin Pharm 2017;39:41-4. [PMID: 27905076 DOI: 10.1007/s11096-016-0403-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
157 Matchar DB, Love SR, Jacobson AK, Edson R, Uyeda L, Phibbs CS, Dolor RJ. The impact of frequency of patient self-testing of prothrombin time on time in target range within VA Cooperative Study #481: The Home INR Study (THINRS), a randomized, controlled trial. J Thromb Thrombolysis 2015;40:17-25. [PMID: 25209313 DOI: 10.1007/s11239-014-1128-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
158 Angiolillo DJ, Goodman SG, Bhatt DL, Eikelboom JW, Price MJ, Moliterno DJ, Cannon CP, Tanguay JF, Granger CB, Mauri L, Holmes DR, Gibson CM, Faxon DP. Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2016 Update. Circ Cardiovasc Interv 2016;9:e004395. [PMID: 27803042 DOI: 10.1161/CIRCINTERVENTIONS.116.004395] [Cited by in Crossref: 68] [Cited by in F6Publishing: 17] [Article Influence: 13.6] [Reference Citation Analysis]
159 Lee SL, Ong TJ, Mazlan-Kepli W, Mageswaran A, Tan KH, Abd-Malek AM, Cronshaw R. Patients’ time in therapeutic range on warfarin among atrial fibrillation patients in Warfarin Medication Therapy Adherence Clinic. World J Cardiol 2021; 13(9): 483-492 [PMID: 34621493 DOI: 10.4330/wjc.v13.i9.483] [Reference Citation Analysis]
160 Leong-Sit P, Healey JS. A New, Simplified Measure of Anticoagulation Control With Warfarin: Potential Role in the Direct Oral Anticoagulant Era. Can J Cardiol 2016;32:1203.e5-7. [PMID: 26922290 DOI: 10.1016/j.cjca.2015.11.018] [Reference Citation Analysis]
161 Blanco-Molina A. [New advances in anticoagulation: is it time to forget about heparin and vitamin K antagonists? Yes]. Rev Clin Esp 2012;212 Suppl 1:3-7. [PMID: 23117646 DOI: 10.1016/S0014-2565(12)70010-3] [Reference Citation Analysis]
162 Katritsis GD, Katritsis DG. Management of Complications in Anticoagulated Patients with Atrial Fibrillation. Arrhythm Electrophysiol Rev 2017;6:167-78. [PMID: 29326831 DOI: 10.15420/aer.2017.23.1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
163 Mueller S, Groth A, Spitzer SG, Schramm A, Pfaff A, Maywald U. Real-world effectiveness and safety of oral anticoagulation strategies in atrial fibrillation: a cohort study based on a German claims dataset. Pragmat Obs Res 2018;9:1-10. [PMID: 29750067 DOI: 10.2147/POR.S156521] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
164 Rose AJ, Hylek EM, Ozonoff A, Ash AS, Reisman JI, Berlowitz DR. Risk-Adjusted Percent Time in Therapeutic Range as a Quality Indicator for Outpatient Oral Anticoagulation: Results of the Veterans Affairs Study To Improve Anticoagulation (VARIA). Circ: Cardiovascular Quality and Outcomes 2011;4:22-9. [DOI: 10.1161/circoutcomes.110.957738] [Cited by in Crossref: 116] [Cited by in F6Publishing: 43] [Article Influence: 10.5] [Reference Citation Analysis]
165 Mouton JP, Blockman M, Sekaggya-Wiltshire C, Semakula J, Waitt C, Pirmohamed M, Cohen K. Improving anticoagulation in sub-Saharan Africa: What are the challenges and how can we overcome them? Br J Clin Pharmacol 2021;87:3056-68. [PMID: 33586223 DOI: 10.1111/bcp.14768] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
166 Norgard NB, Dinicolantonio JJ, Topping TJ, Wee B. Novel anticoagulants in atrial fibrillation stroke prevention. Ther Adv Chronic Dis 2012;3:123-36. [PMID: 23251773 DOI: 10.1177/2040622312438934] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
167 Jobski K, Hoffmann F, Herget-Rosenthal S, Dörks M. Use of oral anticoagulants in German nursing home residents: drug use patterns and predictors for treatment choice. Br J Clin Pharmacol 2018;84:590-601. [PMID: 29148592 DOI: 10.1111/bcp.13474] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
168 Lopes RD, Horowitz JD, Garcia DA, Crowther MA, Hylek EM. Warfarin and acetaminophen interaction: a summary of the evidence and biologic plausibility. Blood 2011;118:6269-73. [PMID: 21911832 DOI: 10.1182/blood-2011-08-335612] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
169 Smith DE, Xuereb CB, Pattison HM, Lip GY, Lane DA. TRial of an Educational intervention on patients' knowledge of Atrial fibrillation and anticoagulant therapy, INR control, and outcome of Treatment with warfarin (TREAT). BMC Cardiovasc Disord 2010;10:21. [PMID: 20487528 DOI: 10.1186/1471-2261-10-21] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
170 Eriksson SE. Secondary prophylactic treatment and long-term prognosis after TIA and different subtypes of stroke. A 25-year follow-up hospital-based observational study. Brain Behav 2017;7:e00603. [PMID: 28127521 DOI: 10.1002/brb3.603] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
171 Mohammed S, Aljundi AH, Kasem M, Alhashemi M, El-Menyar A. Anticoagulation control among patients with nonvalvular atrial fibrillation: A single tertiary cardiac center experience. J Adv Pharm Technol Res 2017;8:14-8. [PMID: 28217549 DOI: 10.4103/2231-4040.197370] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
172 Poli D, Antonucci E, Testa S, Lip GY. A prospective validation of the SAME-TT2R 2 score: how to identify atrial fibrillation patients who will have good anticoagulation control on warfarin. Intern Emerg Med 2014;9:443-7. [PMID: 24652166 DOI: 10.1007/s11739-014-1065-8] [Cited by in Crossref: 54] [Cited by in F6Publishing: 47] [Article Influence: 6.8] [Reference Citation Analysis]
173 Li X, Sun S, Wang Q, Chen B, Zhao Z, Xu X. Assessment of patients' warfarin knowledge and anticoagulation control at a joint physician- and pharmacist-managed clinic in China. Patient Prefer Adherence 2018;12:783-91. [PMID: 29785093 DOI: 10.2147/PPA.S156734] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
174 Clarkesmith DE, Pattison HM, Borg Xuereb C, Lane DA. Developing a Complex Educational-Behavioural Intervention: The TREAT Intervention for Patients with Atrial Fibrillation. Healthcare (Basel) 2016;4:E10. [PMID: 27417598 DOI: 10.3390/healthcare4010010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
175 Krittayaphong R, Winijkul A, Methavigul K, Wongtheptien W, Wongvipaporn C, Wisaratapong T, Kunjara-Na-Ayudhya R, Boonyaratvej S, Komoltri C, Kaewcomdee P, Yindeengam A, Sritara P; COOL-AF Investigators. Risk profiles and pattern of antithrombotic use in patients with non-valvular atrial fibrillation in Thailand: a multicenter study. BMC Cardiovasc Disord 2018;18:174. [PMID: 30144802 DOI: 10.1186/s12872-018-0911-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
176 Kocael A, Eronat AP, Tüzüner MB, Ekmekçi A, Orhan AL, İkizceli İ, Yılmaz-Aydoğan H, Öztürk O. Interpretation of the effect of CYP2C9, VKORC1 and CYP4F2 variants on warfarin dosing adjustment in Turkey. Mol Biol Rep 2019;46:1825-33. [PMID: 30712247 DOI: 10.1007/s11033-019-04634-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
177 Fung E, Patsopoulos NA, Belknap SM, O'Rourke DJ, Robb JF, Anderson JL, Shworak NW, Moore JH. Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin. Semin Thromb Hemost 2012;38:893-904. [PMID: 23041981 DOI: 10.1055/s-0032-1328891] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
178 Matsumura-nakano Y, Shizuta S, Komasa A, Morimoto T, Masuda H, Shiomi H, Goto K, Nakai K, Ogawa H, Kobori A, Kono Y, Kaitani K, Suwa S, Aoyama T, Takahashi M, Sasaki Y, Onishi Y, Mano T, Matsuda M, Motooka M, Tomita H, Inoko M, Wakeyama T, Hagiwara N, Tanabe K, Akao M, Miyauchi K, Yajima J, Hanaoka K, Morino Y, Ando K, Furukawa Y, Nakagawa Y, Nakao K, Kozuma K, Kadota K, Kimura K, Kawai K, Ueno T, Okumura K, Kimura T; On behalf of the OAC-ALONE Study Investigators. Open-Label Randomized Trial Comparing Oral Anticoagulation With and Without Single Antiplatelet Therapy in Patients With Atrial Fibrillation and Stable Coronary Artery Disease Beyond 1 Year After Coronary Stent Implantation: OAC-ALONE Study. Circulation 2019;139:604-16. [DOI: 10.1161/circulationaha.118.036768] [Cited by in Crossref: 65] [Cited by in F6Publishing: 21] [Article Influence: 21.7] [Reference Citation Analysis]
179 Razouki Z, Ozonoff A, Zhao S, Jasuja GK, Rose AJ. Improving Quality Measurement for Anticoagulation: Adding International Normalized Ratio Variability to Percent Time in Therapeutic Range. Circ Cardiovasc Qual Outcomes 2014;7:664-9. [DOI: 10.1161/circoutcomes.114.000804] [Cited by in Crossref: 37] [Cited by in F6Publishing: 17] [Article Influence: 4.6] [Reference Citation Analysis]
180 Yang F, Hellyer JA, Than C, Ullal AJ, Kaiser DW, Heidenreich PA, Hoang DD, Winkelmayer WC, Schmitt S, Frayne SM, Phibbs CS, Turakhia MP. Warfarin utilisation and anticoagulation control in patients with atrial fibrillation and chronic kidney disease. Heart 2017;103:818-26. [PMID: 27852694 DOI: 10.1136/heartjnl-2016-309266] [Cited by in Crossref: 52] [Cited by in F6Publishing: 41] [Article Influence: 8.7] [Reference Citation Analysis]
181 Çelik A, İzci S, Kobat MA, Ateş AH, Çakmak A, Çakıllı Y, Yılmaz MB, Zoghi M; WARFARIN-TR Study Collaborates. The awareness, efficacy, safety, and time in therapeutic range of warfarin in the Turkish population: WARFARIN-TR. Anatol J Cardiol 2016;16:595-600. [PMID: 27004711 DOI: 10.5152/AnatolJCardiol.2015.6474] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
182 Connolly SJ, Crijns HJ, Torp-pedersen C, van Eickels M, Gaudin C, Page RL, Hohnloser SH. Analysis of Stroke in ATHENA: A Placebo-Controlled, Double-Blind, Parallel-Arm Trial to Assess the Efficacy of Dronedarone 400 mg BID for the Prevention of Cardiovascular Hospitalization or Death From Any Cause in Patients With Atrial Fibrillation/Atrial Flutter. Circulation 2009;120:1174-80. [DOI: 10.1161/circulationaha.109.875252] [Cited by in Crossref: 167] [Cited by in F6Publishing: 40] [Article Influence: 12.8] [Reference Citation Analysis]
183 van Rein N, Lijfering WM, Bos MH, Herruer MH, Vermaas HW, van der Meer FJ, Reitsma PH. Objectives and Design of BLEEDS: A Cohort Study to Identify New Risk Factors and Predictors for Major Bleeding during Treatment with Vitamin K Antagonists. PLoS One 2016;11:e0164485. [PMID: 27935941 DOI: 10.1371/journal.pone.0164485] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
184 Krittayaphong R, Phrommintikul A, Ngamjanyaporn P, Siriwattana K, Kanjanarutjawiwat W, Chantrarat T, Rojjarekampai R, Kaewcomdee P, Sonkhammee P; COOL-AF Investigators. Rate of anticoagulant use, and factors associated with not prescribing anticoagulant in older Thai adults with non-valvular atrial fibrillation: A multicenter registry. J Geriatr Cardiol 2019;16:242-50. [PMID: 31080466 DOI: 10.11909/j.issn.1671-5411.2019.03.004] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
185 Marcatto LR, Sacilotto L, Tavares LC, Facin M, Olivetti N, Strunz CMC, Darrieux FCC, Scanavacca MI, Krieger JE, Pereira AC, Santos PCJL. Pharmaceutical Care Increases Time in Therapeutic Range of Patients With Poor Quality of Anticoagulation With Warfarin. Front Pharmacol 2018;9:1052. [PMID: 30298004 DOI: 10.3389/fphar.2018.01052] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
186 Defoe K, Wichart J, Leung K. Time in Therapeutic Range Using a Nomogram for Dose Adjustment of Warfarin in Patients on Hemodialysis With Atrial Fibrillation. Can J Kidney Health Dis 2021;8:20543581211046079. [PMID: 34552757 DOI: 10.1177/20543581211046079] [Reference Citation Analysis]
187 Bista D, Chalmers L, Bereznicki L, Peterson G. Potential use of NOACs in developing countries: pros and cons. Eur J Clin Pharmacol 2014;70:817-28. [PMID: 24817486 DOI: 10.1007/s00228-014-1693-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
188 Wilson AS, Vazquez SR, Saunders JA, Witt DM. Concordance of experienced-based maintenance warfarin dosing vs. algorithm-based dosing. Thrombosis Update 2022;6:100093. [DOI: 10.1016/j.tru.2021.100093] [Reference Citation Analysis]
189 Bruins Slot KM, Berge E. Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation. Cochrane Database Syst Rev 2018;3:CD008980. [PMID: 29509959 DOI: 10.1002/14651858.CD008980.pub3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
190 Harris K, Mant J. Potential impact of new oral anticoagulants on the management of atrial fibrillation-related stroke in primary care. Int J Clin Pract 2013;67:647-55. [PMID: 23621153 DOI: 10.1111/ijcp.12177] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
191 Healey JS, Nair GM. Does catheter ablation for atrial fibrillation increase or reduce neurological insult? Curr Opin Cardiol 2012;27:36-40. [PMID: 22123602 DOI: 10.1097/HCO.0b013e32834d846a] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
192 Singh J, Bhatt DL. Refining the role of antiplatelet therapy for atrial fibrillation. Curr Cardiol Rep 2009;11:239-40. [PMID: 19563721 DOI: 10.1007/s11886-009-0034-8] [Reference Citation Analysis]
193 Durand M, Schnitzer ME, Pang M, Carney G, Eltonsy S, Filion KB, Fisher A, Jun M, Kuo IF, Renoux C, Paterson JM, Quail J, Matteau A; Canadian Network for Observational Drug Effect Studies Investigators. Comparative effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists in nonvalvular atrial fibrillation: a Canadian multicentre observational cohort study. CMAJ Open 2020;8:E877-86. [PMID: 33355273 DOI: 10.9778/cmajo.20200055] [Reference Citation Analysis]
194 Prochaska JH, Göbel S, Keller K, Coldewey M, Ullmann A, Lamparter H, Jünger C, Al-Bayati Z, Baer C, Walter U, Bickel C, ten Cate H, Münzel T, Wild PS. Quality of oral anticoagulation with phenprocoumon in regular medical care and its potential for improvement in a telemedicine-based coagulation service--results from the prospective, multi-center, observational cohort study thrombEVAL. BMC Med 2015;13:14. [PMID: 25616558 DOI: 10.1186/s12916-015-0268-9] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 4.1] [Reference Citation Analysis]
195 Kim J, Jongnarangsin K, Latchamsetty R, Chugh A, Ghanbari H, Crawford T, Yokokawa M, Good E, Bogun F, Pelosi F, Morady F, Oral H. The Optimal Range of International Normalized Ratio for Radiofrequency Catheter Ablation of Atrial Fibrillation During Therapeutic Anticoagulation With Warfarin. Circ Arrhythm Electrophysiol 2013;6:302-9. [DOI: 10.1161/circep.112.000143] [Cited by in Crossref: 30] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
196 Eggebrecht L, Ludolph P, Göbel S, Panova-Noeva M, Arnold N, Nagler M, Bickel C, Lauterbach M, Hardt R, Cate HT, Lackner KJ, Espinola-Klein C, Münzel T, Prochaska JH, Wild PS. Cost saving analysis of specialized, eHealth-based management of patients receiving oral anticoagulation therapy: Results from the thrombEVAL study. Sci Rep 2021;11:2577. [PMID: 33510343 DOI: 10.1038/s41598-021-82076-9] [Reference Citation Analysis]
197 Perino AC, Shrader P, Turakhia MP, Ansell JE, Gersh BJ, Fonarow GC, Go AS, Kaiser DW, Hylek EM, Kowey PR, Singer DE, Thomas L, Steinberg BA, Peterson ED, Piccini JP, Mahaffey KW. Comparison of Patient-Reported Care Satisfaction, Quality of Warfarin Therapy, and Outcomes of Atrial Fibrillation: Findings From the ORBIT - AF Registry. J Am Heart Assoc 2019;8:e011205. [PMID: 31023126 DOI: 10.1161/JAHA.118.011205] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
198 Pryce R, Bernaitis N, Davey AK, Badrick T, Anoopkumar-Dukie S. The Use of Fish Oil with Warfarin Does Not Significantly Affect either the International Normalised Ratio or Incidence of Adverse Events in Patients with Atrial Fibrillation and Deep Vein Thrombosis: A Retrospective Study. Nutrients 2016;8:E578. [PMID: 27657121 DOI: 10.3390/nu8090578] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
199 Zhang JT, Chen KP, Zhang S. Efficacy and safety of oral anticoagulants versus aspirin for patients with atrial fibrillation: a meta-analysis. Medicine (Baltimore) 2015;94:e409. [PMID: 25634169 DOI: 10.1097/MD.0000000000000409] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
200 Schein JR, White CM, Nelson WW, Kluger J, Mearns ES, Coleman CI. Vitamin K antagonist use: evidence of the difficulty of achieving and maintaining target INR range and subsequent consequences. Thromb J 2016;14:14. [PMID: 27303213 DOI: 10.1186/s12959-016-0088-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
201 Turakhia MP. Quality of stroke prevention care in atrial fibrillation: many moving targets. Circ Cardiovasc Qual Outcomes 2011;4:5-8. [PMID: 21245458 DOI: 10.1161/CIRCOUTCOMES.110.959890] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
202 Ewen S, Rettig-Ewen V, Mahfoud F, Böhm M, Laufs U. Drug adherence in patients taking oral anticoagulation therapy. Clin Res Cardiol 2014;103:173-82. [PMID: 23999974 DOI: 10.1007/s00392-013-0616-8] [Cited by in Crossref: 37] [Cited by in F6Publishing: 28] [Article Influence: 4.1] [Reference Citation Analysis]
203 Oldgren J, Hijazi Z, Lindbäck J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Granger CB, Hylek EM, Lopes RD, Siegbahn A, Yusuf S, Wallentin L; RE-LY and ARISTOTLE Investigators. Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation. Circulation 2016;134:1697-707. [PMID: 27569438 DOI: 10.1161/CIRCULATIONAHA.116.022802] [Cited by in Crossref: 53] [Cited by in F6Publishing: 27] [Article Influence: 8.8] [Reference Citation Analysis]
204 Chau KH, Scherzer R, Grunfeld C, Hsue PY, Shlipak MG. CHA2DS2-VASc Score, Warfarin Use, and Risk for Thromboembolic Events Among HIV-Infected Persons With Atrial Fibrillation. J Acquir Immune Defic Syndr 2017;76:90-7. [PMID: 28797024 DOI: 10.1097/QAI.0000000000001470] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
205 Lee TC, Qian M, Lip GYH, Di Tullio MR, Graham S, Mann DL, Nakanishi K, Teerlink JR, Freudenberger RS, Sacco RL, Mohr JP, Labovitz AJ, Ponikowski P, Lok DJ, Estol C, Anker SD, Pullicino PM, Buchsbaum R, Levin B, Thompson JLP, Homma S, Ye S; WARCEF Investigators. Heart Failure Severity and Quality of Warfarin Anticoagulation Control (From the WARCEF Trial). Am J Cardiol 2018;122:821-7. [PMID: 30037426 DOI: 10.1016/j.amjcard.2018.05.024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
206 Szummer K, Gasparini A, Eliasson S, Ärnlöv J, Qureshi AR, Bárány P, Evans M, Friberg L, Carrero JJ. Time in Therapeutic Range and Outcomes After Warfarin Initiation in Newly Diagnosed Atrial Fibrillation Patients With Renal Dysfunction. J Am Heart Assoc 2017;6:e004925. [PMID: 28249846 DOI: 10.1161/JAHA.116.004925] [Cited by in Crossref: 35] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
207 Wasniewski S, Consuegra-Sánchez L, Conesa-Zamora P, García de Guadiana-Romualdo L, Ramos-Ruiz P, Merelo-Nicolás M, Clavel-Ruipérez FG, Alburquerque-González B, Soria-Arcos F, Castillo-Moreno JA. Low Performance of a Clinical-Genetic Model in the Estimation of Time in Therapeutic Range in Acenocoumarol-Adherent Patients with Nonvalvular Atrial Fibrillation: The Quality of Anticoagulation Challenge. Biomed Res Int 2018;2018:8012747. [PMID: 30417015 DOI: 10.1155/2018/8012747] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
208 Holmes DR, Schwartz RS. Left Atrial Appendage Occlusion Eliminates the Need for Warfarin. Circulation 2009;120:1919-26. [DOI: 10.1161/circulationaha.108.844761] [Cited by in Crossref: 28] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
209 Bajorek B. A review of the safety of anticoagulants in older people using the medicines management pathway: weighing the benefits against the risks. Ther Adv Drug Saf 2011;2:45-58. [PMID: 25083201 DOI: 10.1177/2042098611400495] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
210 Djalali S, Valeri F, Gerber B, Meli DN, Senn O. Anticoagulation Control in Swiss Primary Care: Time in Therapeutic Range Percentages Exceed Benchmarks of Phase III Trials. Clin Appl Thromb Hemost 2017;23:685-95. [PMID: 27056934 DOI: 10.1177/1076029616642514] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
211 Gil Núñez A. Avances en la prevención de la isquemia cerebral por fibrilación auricular. Neurología 2010;25:401-8. [DOI: 10.1016/j.nrl.2010.03.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
212 Eikelboom JW, Weitz JI. New Anticoagulants. Circulation 2010;121:1523-32. [DOI: 10.1161/circulationaha.109.853119] [Cited by in Crossref: 208] [Cited by in F6Publishing: 55] [Article Influence: 17.3] [Reference Citation Analysis]
213 Dobesh PP, Fanikos J. Direct Oral Anticoagulants for the Prevention of Stroke in Patients with Nonvalvular Atrial Fibrillation: Understanding Differences and Similarities. Drugs 2015;75:1627-44. [PMID: 26370208 DOI: 10.1007/s40265-015-0452-4] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
214 Rodriguez F, Hong C, Chang Y, Oertel LB, Singer DE, Green AR, López L. Limited English proficient patients and time spent in therapeutic range in a warfarin anticoagulation clinic. J Am Heart Assoc 2013;2:e000170. [PMID: 23832325 DOI: 10.1161/JAHA.113.000170] [Cited by in Crossref: 16] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
215 Bhusri S, Ansell J. New anticoagulants in atrial fibrillation: an update for clinicians. Ther Adv Chronic Dis 2012;3:37-45. [PMID: 23251767 DOI: 10.1177/2040622311424805] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
216 Ahmad Y, Lip GY. Stroke prevention in atrial fibrillation: concepts and controversies. Curr Cardiol Rev 2012;8:290-301. [PMID: 22920480 DOI: 10.2174/157340312803760820] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
217 Plunkett O, Lip GY. The Potential Role of Edoxaban in Stroke Prevention Guidelines. Arrhythm Electrophysiol Rev 2014;3:40-3. [PMID: 26835064 DOI: 10.15420/aer.2011.3.1.40] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
218 Szummer K, Carrero JJ. Warfarin therapy for atrial fibrillation in haemodialysis patients: mind the (evidence) gap. Nephrology Dialysis Transplantation 2015;30:337-9. [DOI: 10.1093/ndt/gfu412] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
219 Lin KJ, Singer DE, Glynn RJ, Blackley S, Zhou L, Liu J, Dube G, Oertel LB, Schneeweiss S. Prediction Score for Anticoagulation Control Quality Among Older Adults. J Am Heart Assoc 2017;6:e006814. [PMID: 28982676 DOI: 10.1161/JAHA.117.006814] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
220 Gallagher AM, van Staa TP, Murray-Thomas T, Schoof N, Clemens A, Ackermann D, Bartels DB. Population-based cohort study of warfarin-treated patients with atrial fibrillation: incidence of cardiovascular and bleeding outcomes. BMJ Open 2014;4:e003839. [PMID: 24468720 DOI: 10.1136/bmjopen-2013-003839] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 5.1] [Reference Citation Analysis]
221 Yamaji H, Murakami T, Hina K, Higashiya S, Kawamura H, Murakami M, Kamikawa S, Hirohata S, Kusachi S. Usefulness of dabigatran etexilate as periprocedural anticoagulation therapy for atrial fibrillation ablation. Clin Drug Investig 2013;33:409-18. [PMID: 23572324 DOI: 10.1007/s40261-013-0081-1] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 4.0] [Reference Citation Analysis]
222 Paradise HT, Berlowitz DR, Ozonoff A, Miller DR, Hylek EM, Ash AS, Jasuja GK, Zhao S, Reisman JI, Rose AJ. Outcomes of anticoagulation therapy in patients with mental health conditions. J Gen Intern Med 2014;29:855-61. [PMID: 24549520 DOI: 10.1007/s11606-014-2784-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
223 Toorop MMA, Chen Q, Kruip MJHA, van der Meer FJM, Nierman MC, Faber L, Goede L, Cannegieter SC, Lijfering WM. Switching from vitamin K antagonists to direct oral anticoagulants in non-valvular atrial fibrillation patients: Does low time in therapeutic range affect persistence? J Thromb Haemost 2021. [PMID: 34779140 DOI: 10.1111/jth.15592] [Reference Citation Analysis]
224 Steinberg BA, Piccini JP. Anticoagulation in atrial fibrillation. BMJ 2014;348:g2116. [PMID: 24733535 DOI: 10.1136/bmj.g2116] [Cited by in Crossref: 52] [Cited by in F6Publishing: 36] [Article Influence: 6.5] [Reference Citation Analysis]
225 Korpallová B, Samoš M, Bolek T, Škorňová I, Kovář F, Kubisz P, Staško J, Mokáň M. Role of thromboelastography and rotational thromboelastometry in the management of cardiovascular diseases.Clin Appl Thromb Hemost. 2018;24:1199-1207. [PMID: 30041546 DOI: 10.1177/1076029618790092] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
226 da Silva RM. Novel oral anticoagulants in non-valvular atrial fibrillation. Cardiovasc Hematol Agents Med Chem 2014;12:3-8. [PMID: 25470147 DOI: 10.2174/187152571201141201091848] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
227 Rose AJ, Hylek EM, Berlowitz DR, Ash AS, Reisman JI, Ozonoff A. Prompt repeat testing after out-of-range INR values: a quality indicator for anticoagulation care. Circ Cardiovasc Qual Outcomes 2011;4:276-82. [PMID: 21505156 DOI: 10.1161/CIRCOUTCOMES.110.960096] [Cited by in Crossref: 39] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
228 Madhavan M, Hu TY, Gersh BJ, Roger VL, Killian J, Weston SA, Graff-Radford J, Asirvatham SJ, Chamberlain AM. Efficacy of Warfarin Anticoagulation and Incident Dementia in a Community-Based Cohort of Atrial Fibrillation. Mayo Clin Proc 2018;93:145-54. [PMID: 29329798 DOI: 10.1016/j.mayocp.2017.09.021] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 7.5] [Reference Citation Analysis]
229 Kaye JB, Schultz LE, Steiner HE, Kittles RA, Cavallari LH, Karnes JH. Warfarin Pharmacogenomics in Diverse Populations. Pharmacotherapy 2017;37:1150-63. [PMID: 28672100 DOI: 10.1002/phar.1982] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 6.4] [Reference Citation Analysis]
230 Huber K, Connolly SJ, Kher A, Christory F, Dan GA, Hatala R, Kiss RG, Meier B, Merkely B, Pieske B, Potpara T, Stępińska J, Klun NV, Vinereanu D, Widimský P. Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation. Int J Clin Pract 2013;67:516-26. [PMID: 23557519 DOI: 10.1111/ijcp.12147] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
231 Grothusen C, Attmann T, Friedrich C, Freitag-Wolf S, Haake N, Cremer J, Schöttler J. Predictors for long-term outcome and quality of life of patients after cardiac surgery with prolonged intensive care unit stay. Interv Med Appl Sci 2013;5:3-9. [PMID: 24265881 DOI: 10.1556/IMAS.5.2013.1.1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
232 Keller K, Göbel S, Ten Cate V, Panova-Noeva M, Eggebrecht L, Nagler M, Coldewey M, Foebel M, Bickel C, Lauterbach M, Espinola-Klein C, Lackner KJ, Cate HT, Münzel T, Wild PS, H Prochaska J. Telemedicine-Based Specialized Care Improves the Outcome of Anticoagulated Individuals with Venous Thromboembolism-Results from the thrombEVAL Study. J Clin Med 2020;9:E3281. [PMID: 33066188 DOI: 10.3390/jcm9103281] [Reference Citation Analysis]
233 Ning X, Kuang Y, Yang G, Xie J, Miao D, Guo C, Huang Z. Influence of renal insufficiency on anticoagulant effects and safety of warfarin in Chinese patients: analysis from a randomized controlled trial. Naunyn Schmiedebergs Arch Pharmacol 2021;394:1275-83. [PMID: 33404689 DOI: 10.1007/s00210-020-02037-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]